# Phase 3 Trial to Evaluate the Efficacy and Safety of YYC506.

> **NCT04858308** · PHASE3 · UNKNOWN · sponsor: **Yooyoung Pharmaceutical Co., Ltd.** · enrollment: 554 (estimated)

## Conditions studied

- Dyslipidemias

## Interventions

- **DRUG:** YYC506
- **DRUG:** Control
- **DRUG:** YYC506 Placebo
- **DRUG:** Control Placebo

## Key facts

- **NCT ID:** NCT04858308
- **Lead sponsor:** Yooyoung Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-29
- **Primary completion:** 2021-05-31
- **Final completion:** 2022-01-31
- **Target enrollment:** 554 (ESTIMATED)
- **Last updated:** 2021-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04858308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04858308, "Phase 3 Trial to Evaluate the Efficacy and Safety of YYC506.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04858308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*